Cargando…
Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab
Head and neck squamous cell carcinomas (HNSCCs) are a type of cancer originating in the mucosal epithelium of the mouth, pharynx, and larynx, the sixth most common cancer in the world. However, there is no effective treatment for HNSCCs. More than 90% of HNSCCs overexpress epidermal growth factor re...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409433/ https://www.ncbi.nlm.nih.gov/pubmed/36012290 http://dx.doi.org/10.3390/ijms23169014 |
_version_ | 1784774849686667264 |
---|---|
author | Liu, Shujie Yan, Shuai Zhu, Jie Lu, Ruiqing Kang, Chujie Tang, Kang Zeng, Jinfeng Ding, Mingmei Guo, Zixiang Lai, Xianxin Jiang, Yinan Wu, Siqing Zhou, Lihua Sun, Litao Zhou, Zhong-Wei |
author_facet | Liu, Shujie Yan, Shuai Zhu, Jie Lu, Ruiqing Kang, Chujie Tang, Kang Zeng, Jinfeng Ding, Mingmei Guo, Zixiang Lai, Xianxin Jiang, Yinan Wu, Siqing Zhou, Lihua Sun, Litao Zhou, Zhong-Wei |
author_sort | Liu, Shujie |
collection | PubMed |
description | Head and neck squamous cell carcinomas (HNSCCs) are a type of cancer originating in the mucosal epithelium of the mouth, pharynx, and larynx, the sixth most common cancer in the world. However, there is no effective treatment for HNSCCs. More than 90% of HNSCCs overexpress epidermal growth factor receptors (EGFRs). Although small molecule inhibitors and monoclonal antibodies have been developed to target EGFRs, few EGFR-targeted therapeutics are approved for clinical use. Ferroptosis is a new kind of programmed death induced by the iron catalyzed excessive peroxidation of polyunsaturated fatty acids. A growing body of evidence suggests that ferroptosis plays a pivotal role in inhibiting the tumor process. However, whether and how ferroptosis-inducers (FINs) play roles in hindering HNSCCs are unclear. In this study, we analyzed the sensitivity of different HNSCCs to ferroptosis-inducers. We found that only tongue squamous cell carcinoma cells and laryngeal squamous cell carcinoma cells, but not nasopharyngeal carcinoma cells, actively respond to ferroptosis-inducers. The different sensitivities of HNSCC cells to ferroptosis induction may be attributed to the expression of KRAS and ferritin heavy chain (FTH1) since a high level of FTH1 is associated with the poor prognostic survival of HNSCCs, but knocked down FTH1 can promote HNSCC cell death. Excitingly, the ferroptosis-inducer RSL3 plays a synthetic role with EGFR monoclonal antibody Cetuximab to inhibit the survival of nasopharyngeal carcinoma cells (CNE-2), which are insensitive to both ferroptosis induction and EGFR inhibition due to a high level of FTH1 and a low level of EGFR, respectively. Our findings prove that FTH1 plays a vital role in ferroptosis resistance in HNSCCs and also provide clues to target HNSCCs resistant to ferroptosis induction and/or EGFR inhibition. |
format | Online Article Text |
id | pubmed-9409433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94094332022-08-26 Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab Liu, Shujie Yan, Shuai Zhu, Jie Lu, Ruiqing Kang, Chujie Tang, Kang Zeng, Jinfeng Ding, Mingmei Guo, Zixiang Lai, Xianxin Jiang, Yinan Wu, Siqing Zhou, Lihua Sun, Litao Zhou, Zhong-Wei Int J Mol Sci Article Head and neck squamous cell carcinomas (HNSCCs) are a type of cancer originating in the mucosal epithelium of the mouth, pharynx, and larynx, the sixth most common cancer in the world. However, there is no effective treatment for HNSCCs. More than 90% of HNSCCs overexpress epidermal growth factor receptors (EGFRs). Although small molecule inhibitors and monoclonal antibodies have been developed to target EGFRs, few EGFR-targeted therapeutics are approved for clinical use. Ferroptosis is a new kind of programmed death induced by the iron catalyzed excessive peroxidation of polyunsaturated fatty acids. A growing body of evidence suggests that ferroptosis plays a pivotal role in inhibiting the tumor process. However, whether and how ferroptosis-inducers (FINs) play roles in hindering HNSCCs are unclear. In this study, we analyzed the sensitivity of different HNSCCs to ferroptosis-inducers. We found that only tongue squamous cell carcinoma cells and laryngeal squamous cell carcinoma cells, but not nasopharyngeal carcinoma cells, actively respond to ferroptosis-inducers. The different sensitivities of HNSCC cells to ferroptosis induction may be attributed to the expression of KRAS and ferritin heavy chain (FTH1) since a high level of FTH1 is associated with the poor prognostic survival of HNSCCs, but knocked down FTH1 can promote HNSCC cell death. Excitingly, the ferroptosis-inducer RSL3 plays a synthetic role with EGFR monoclonal antibody Cetuximab to inhibit the survival of nasopharyngeal carcinoma cells (CNE-2), which are insensitive to both ferroptosis induction and EGFR inhibition due to a high level of FTH1 and a low level of EGFR, respectively. Our findings prove that FTH1 plays a vital role in ferroptosis resistance in HNSCCs and also provide clues to target HNSCCs resistant to ferroptosis induction and/or EGFR inhibition. MDPI 2022-08-12 /pmc/articles/PMC9409433/ /pubmed/36012290 http://dx.doi.org/10.3390/ijms23169014 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Liu, Shujie Yan, Shuai Zhu, Jie Lu, Ruiqing Kang, Chujie Tang, Kang Zeng, Jinfeng Ding, Mingmei Guo, Zixiang Lai, Xianxin Jiang, Yinan Wu, Siqing Zhou, Lihua Sun, Litao Zhou, Zhong-Wei Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab |
title | Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab |
title_full | Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab |
title_fullStr | Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab |
title_full_unstemmed | Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab |
title_short | Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab |
title_sort | combination rsl3 treatment sensitizes ferroptosis- and egfr-inhibition-resistant hnsccs to cetuximab |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409433/ https://www.ncbi.nlm.nih.gov/pubmed/36012290 http://dx.doi.org/10.3390/ijms23169014 |
work_keys_str_mv | AT liushujie combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT yanshuai combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT zhujie combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT luruiqing combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT kangchujie combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT tangkang combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT zengjinfeng combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT dingmingmei combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT guozixiang combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT laixianxin combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT jiangyinan combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT wusiqing combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT zhoulihua combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT sunlitao combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab AT zhouzhongwei combinationrsl3treatmentsensitizesferroptosisandegfrinhibitionresistanthnsccstocetuximab |